EICHOR
● Active Not Recruiting
A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors
Condition: Pancreatic Ductal Adenocarcinoma · Non-small Cell Lung Cancer · Colorectal Cancer · Sponsor: Eli Lilly and Company
About this study
The main purpose of the study is to assess whether the study drug, LY4066434, is safe and tolerable when administered to participants with locally advanced or metastatic solid tumors with certain KRAS mutations. LY4066434 will be given alone or in combination with other treatments. The study will have 2 parts: monotherapy dose escalation and dose optimization. The study is expected to last up to approximately 5 years.
This description comes directly from the study's public registry record.
Talk to the study team
No contact information is available for this study as per the public registry record.
Always discuss trial participation with your own doctor first.
Locations (45)
| University of Alabama at Birmingham | Birmingham, Alabama, United States | — |
| Mayo Clinic | Phoenix, Arizona, United States | — |
| City of Hope | Duarte, California, United States | — |
| University of California, Los Angeles (UCLA) | Santa Monica, California, United States | — |
| Yale University School of Medicine - Yale Cancer Center | New Haven, Connecticut, United States | — |
| The University of Chicago Medical Center (UCMC) | Chicago, Illinois, United States | — |
| Indiana University (IU) | Indianapolis, Indiana, United States | — |
| Massachusetts General Hospital | Boston, Massachusetts, United States | — |
| Dana-Farber Cancer Institute | Boston, Massachusetts, United States | — |
| South Texas Accelerated Research Therapeutics (START) Midwest | Grand Rapids, Michigan, United States | — |
| Columbia University | New York, New York, United States | — |
| David H. Koch Center for Cancer Care at Memorial Sloan Kettering Cancer Center | New York, New York, United States | — |
+ 33 more locations — full list on the registry record.
Follow this study
Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.
We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06607185